

THE PROSTATE CANCER ADVISORY COUNCIL 2020 ANNUAL REPORT



Table of Contents

- I. Situation Analysis
- II. 2021 PCAC Proposed Membership Renewals
- III. Executive Summary
- IV. Goal Focus 2021

<http://prostatecanceradvisorycouncil.org/>

Situation Analysis

The Florida Prostate Cancer Advisory Council (PCAC) was established in 2004 by state statute 381.911 and remains under the direction of the University of Florida Prostate Disease Center (UFPDC). The task of PCAC is to advise the governor, state surgeon general and state legislature on statewide issues regarding prostate cancer incidence and mortality as well as related health disparities for access to care and prostate cancer treatment. PCAC is a collaborative, multi-institutional and inter-disciplinary advisory body focused on a communication platform that promotes education and awareness as well as improved detection and management of prostate cancer statewide. PCAC is required to file an annual report update to the Governor, State Surgeon General and the Florida Legislature.

Membership in the UFPDC PCAC is by appointment of the executive director of the UFPDC in consultation with the Department of Health's Comprehensive Cancer Control Program and state surgeon general to cover a geographically and institutionally diverse advisory council that shall consist of 9 members:

- Two persons from prostate cancer survivor groups or cancer-related advocacy groups
- Four persons, one of whom is a physician licensed under chapter 458, one of whom is a physician licensed under chapter 459, one of whom is a scientist, one of whom is the executive director of the UFPDC or designee
- Three persons who are engaged in the practice of cancer related medical specialty from health organizations committed to cancer research and control

2021 PCAC Proposed Membership Renewals:

- Raymond W. Pak, M.D., M.B.A
- Statute: Cancer Related Specialty
- Term: January 2021 - January 2023 2 Years

- Julio Pow-Sang, MD
- Statute: Cancer Related Specialty
- Term: January 2021 – January 2025 4 Years

- Tom Stringer, MD
- Statute: Executive Director, UFPDC/PCAC
- Term: January 2021 – January 2022 1 Year

- Megan Wessel, MPH
- Statute: Patient Advocate/Prostate Cancer Survivor Group
- Term: January 2021 – January 2023 2 Years

- Matthew C. Abramowitz, MD
- Statute: Researcher/Scientist
- Term: January 2020 – January 2022 2 Years

- Nicole Bixler, DO, MBA, FACOFP
- Statute: Medical Doctor/ physician licensed under chapter 459 (D.O.)
- Term: January 2021 – January 2023 2 Years

- Mr. Edward Droste
- Statute: Patient Advocate/Prostate Cancer Survivor Group
- Term: January 2021 - January 2022 1 Year

- Julio Hajdenberg, MD
- Statute: Cancer Related Specialty
- Term: January 2021 - January 2023 2 Years

- Ali Kasraeian, MD
- Statute: Medical Doctor/ physician licensed under 458 (M.D.)
- Term: January 2021 - January 2023 2 Years

Executive Summary

The 2020 annual meeting of PCAC was held as a virtual meeting on Saturday November 7th. Participants included PCAC board members and invited guests. Expert speakers addressed prostate cancer education efforts at the national and regional levels as well as racial disparities in the incidence of prostate cancer, including access to treatment and clinical trials. Institutional leaders represented UF Gainesville, UF Jacksonville,

Mayo Clinic Jacksonville, University of Miami, Orlando Health and H. Lee Moffitt Cancer Center. The DOH was represented by the State Surgeon General, Dr. Scott Rivkees. The Florida Cancer Control and Research Advisory Council (CCRAB) was represented by Chairperson Dr. Clement Gwede and the Florida Biomedical Research Advisory Council (BRAC) was represented by Chairperson Dr. Daniel Armstrong.

PCAC work goals for 2020 included ongoing collaboration with our sister state organizations CCRAB and BRAC. For the last year that has included efforts focused on the completion of the 2020-2025 state cancer plan especially as it relates to prostate cancer screening and risk assessment. Efforts include mechanisms to improve the shared decision-making process as well as providing focus on populations at higher risk for aggressive prostate cancer. The objective remains to achieve measurable improvements in the percentage of men both discussing and undergoing screening for prostate cancer.

PCAC remains dedicated to be the reliable source of prostate cancer information for patients, providers and advocates across the state and region. This year the website was enhanced and improved to a more user-friendly format (<http://prostatecanceradvisorycouncil.org/>).

With education as a priority, PCAC seeks like-minded partners. The Centers for Disease Prevention and Control (CDC) has expanded its educational model in collaboration with PCAC, including the development and introduction this fall of Nathan, an interactive tool for discussion of prostate cancer screening and treatment. This Avatar model provides both patients and providers with a platform for more meaningful understanding and discussion of prostate cancer risk. Additionally, PCAC initiated a collaboration this past year with the Prostate Health Education Network (PHEN). PHEN was established in 2003 in partnership with the Dana-Farber Institute with a mission to eliminate prostate cancer disparity in African-American men. PHEN strives to raise awareness of prostate clinical trials and to increase clinical trial understanding and participation among African-American males.

The 2020 PCAC meeting emphasized discussions on education and diversity issues. Dr. Lisa Richardson from the CDC updated the council on focused prostate education models. Dr. Keith Crawford from PHEN gave an informative talk on efforts to enlist African American men in prostate cancer clinical trials. Additional speakers included Ashley Gordon, a senior University of Florida medical student, who addressed the potential biological and sociological sources of prostate cancer racial disparities. Dr. Folakemi Odedina shared her work on the development of a predictive behavioral model of prostate cancer disparities among black men. She proposed the implementation of cost-effective, community-based intervention programs in minority and underserved communities. Dr. Samsun Lamptang addressed a new templated prostate biopsy model to better sample areas of the prostate more at risk for aggressive prostate cancer in black men. Lastly, Drs. Gwede and Armstrong updated the council on the far-reaching cancer prevention and research activities of CCRAB and BRAC respectively. The council members and guests were thoughtfully and comprehensively updated by State Surgeon General, Dr. Scott Rivkees, on state health matters, including the broadly impacting pandemic.

The overarching goal of PCAC is to serve as the voice of patients, advocates and scientists in regards to the impact of prostate cancer on Floridians. In so doing, PCAC strives to be the reliable source of updated prostate cancer education in broad collaboration with their health care partners across the state. PCAC is uniquely comprised of scientists, physicians, and patient advocates representing diverse communities and institutions. The Council is dedicated to the improvement of prostate cancer related outcomes across the state.

Goal Focus 2021

1. Continue collaboration with statewide cancer councils (CCRAB, BRAC) to support the statewide cancer plan and to seek funded research support for prostate cancer.
2. Continue collaboration with national partners (CDC, PHEN, AUA) to expand educational efforts including the enrollment of at-risk populations into prostate cancer clinical trials.
3. Seek partners in multiple practice settings to improve access to care as well as quality of care.
4. Continue efforts to broaden and update prostate cancer education for patients, advocates and providers in the state of Florida.

Respectfully Submitted by

A handwritten signature in cursive script that reads "Thomas F. Stringer, MD".

Thomas F. Stringer, MD
Executive Director
Prostate Cancer Advisory Council